Correction
for
Sreekumar et al., J. Natl. Cancer Inst. 96 (11) 834-843.
JNCI Journal of the National Cancer Institute 2004 96(14):1112; doi:10.1093/jnci/djh222
© 2004 by Oxford University Press
© 2004 Oxford University Press
Erratum
"Humoral Immune Response to
-Methylacyl-CoA Racemase and Prostate
Cancer" by Sreekumar et al. [J Natl Cancer Inst 2004;96:834–43
(Issue 11)]. On page 840, the
y-axis of Fig.
3, A was incorrect.
The corrected Fig.
3 is below. The authors regret the error.
View larger version (24K):
[in this window]
[in a new window]
|
Fig. 3. Immunoblot-based validation and titration of the -methylacyl-CoA racemase (AMACR) humoral response. A) Normalized population mean ratios for AMACR humoral immune response from 259 control subjects and 151 patients with prostate cancer (PCA) as assessed by high-throughput immunoblot analysis. Error bars represent 95% confidence intervals. B) Serial dilutions (1:25 to 1:400) of sera from four randomly selected patients with prostate cancer and two control subjects were analyzed for AMACR humoral response by using immunoblot analysis. C) Immunoblot band intensities for AMACR reactivity from five randomly selected patients with prostate cancer were subjected to densitometry and normalized to mean intensity of positive control sera and plotted against serum dilution to generate a graphical representation of AMACR reactivity.
|
|
CiteULike 
Connotea 
Del.icio.us What's this?
